These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30394548)

  • 1. Eligibility for subcutaneous implantable cardioverter defibrillators in the adult congenital heart disease population.
    Garside H; Leyva F; Hudsmith L; Marshall H; de Bono J
    Pacing Clin Electrophysiol; 2019 Jan; 42(1):65-70. PubMed ID: 30394548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for subcutaneous implantable cardioverter-defibrillator in congenital heart disease.
    Wang L; Javadekar N; Rajagopalan A; Rogovoy NM; Haq KT; Broberg CS; Tereshchenko LG
    Heart Rhythm; 2020 May; 17(5 Pt B):860-869. PubMed ID: 32354451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease.
    Zormpas C; Silber-Peest AS; Eiringhaus J; Hillmann HAK; Hohmann S; Müller-Leisse J; Westhoff-Bleck M; Veltmann C; Duncker D
    ESC Heart Fail; 2021 Apr; 8(2):1502-1508. PubMed ID: 33538124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential eligibility of congenital heart disease patients for subcutaneous implantable cardioverter-defibrillator based on surface electrocardiogram mapping.
    Zeb M; Curzen N; Veldtman G; Yue A; Roberts P; Wilson D; Morgan J
    Europace; 2015 Jul; 17(7):1059-67. PubMed ID: 25678600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Conventional and Right-Sided ECG Screening for Subcutaneous ICD in a Tetralogy of Fallot Population.
    Alonso P; Osca J; Cano O; Pimenta P; Andrés A; Yagüe J; Millet J; Rueda J; Sancho-Tello MJ
    Pacing Clin Electrophysiol; 2017 Feb; 40(2):145-153. PubMed ID: 28070890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA; Hawkins NM; Shaw M; Patwala AY; Pettit SJ; Wright DJ
    Europace; 2014 Jul; 16(7):1015-21. PubMed ID: 24351884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M; Moore JP; Sreeram N; von Alvensleben JC; Shah A; Batra A; Law I; Sanatani S; Thomas V; Nik-Ahd F; Williams S; Nosavan N; Maldonado J; Hart A; Nguyen T; Balaji S
    Heart Rhythm; 2018 May; 15(5):703-707. PubMed ID: 29309839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
    Guo L; Zhang M; Hu M; Wang B; Wang J; Zuo L; Yang W; Liu B; Liu L
    Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With Congenital Heart Disease.
    Moore JP; Mondésert B; Lloyd MS; Cook SC; Zaidi AN; Pass RH; John AS; Fish FA; Shannon KM; Aboulhosn JA; Khairy P;
    Circ Arrhythm Electrophysiol; 2016 Sep; 9(9):. PubMed ID: 27635073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillator therapy to reduce sudden cardiac death in adults with congenital heart disease: A registry study.
    Slater TA; Cupido B; Parry H; Drozd M; Blackburn ME; Hares D; Pepper CB; Birkitt L; Cullington D; Witte KK; Oliver J; English KM; Sengupta A
    J Cardiovasc Electrophysiol; 2020 Aug; 31(8):2086-2092. PubMed ID: 32583559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillators in adults with congenital heart disease: a systematic review and meta-analysis.
    Vehmeijer JT; Brouwer TF; Limpens J; Knops RE; Bouma BJ; Mulder BJ; de Groot JR
    Eur Heart J; 2016 May; 37(18):1439-48. PubMed ID: 26873095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N; Olivotto I; Olde Nordkamp LR; Baldini K; Fumagalli C; Brouwer TF; Knops RE; Cecchi F
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and specificity of the subcutaneous implantable cardioverter defibrillator pre-implant screening tool.
    Zeb M; Curzen N; Allavatam V; Wilson D; Yue A; Roberts P; Morgan J
    Int J Cardiol; 2015 Sep; 195():205-9. PubMed ID: 26048376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
    Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study.
    Conte G; Cattaneo F; de Asmundis C; Berne P; Vicentini A; Namdar M; Scalone A; Klersy C; Caputo ML; Demarchi A; Özkartal T; Salghetti F; Casu G; Passarelli I; Mameli S; Shah D; Burri H; De Ferrari G; Brugada P; Auricchio A
    Europace; 2022 May; 24(5):845-854. PubMed ID: 34499723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defibrillators in adult congenital heart disease: Long-term risk of appropriate shocks, inappropriate shocks, and complications.
    Moore BM; Cao J; Cordina RL; McGuire MA; Celermajer DS
    Pacing Clin Electrophysiol; 2020 Jul; 43(7):746-753. PubMed ID: 32495949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiographic Eligibility for Subcutaneous Implantable Cardioverter Defibrillator: Evaluation during Bicycle Exercise.
    Ziacchi M; Corzani A; Diemberger I; Martignani C; Marziali A; Mazzotti A; Massaro G; Rapezzi C; Biffi M; Boriani G
    Heart Lung Circ; 2016 May; 25(5):476-83. PubMed ID: 27044657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year outcomes in adult patients with congenital heart disease and implantable cardioverter-defibrillators.
    Brouillard AM; Al-Hammadi N; Hunt C; Barger P; Ludbrook P; Gleva MJ
    Int J Cardiol; 2020 Aug; 313():39-45. PubMed ID: 32160963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesion-specific differences for implantable cardioverter defibrillator therapies in adults with congenital heart disease.
    Kella DK; Merchant FM; Veledar E; Book W; Lloyd MS
    Pacing Clin Electrophysiol; 2014 Nov; 37(11):1492-8. PubMed ID: 24889130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.